Connection

ALEXANDER KAY to Anti-HIV Agents

This is a "connection" page, showing publications ALEXANDER KAY has written about Anti-HIV Agents.
Connection Strength

1.591
  1. Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis. 2023 01 06; 76(1):10-17.
    View in: PubMed
    Score: 0.595
  2. Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis. 2021 08 02; 73(3):e580-e586.
    View in: PubMed
    Score: 0.539
  3. HIV-associated drug-resistant TB: expanded treatment options and emerging threats. Curr Opin HIV AIDS. 2026 Mar 01; 21(2):172-179.
    View in: PubMed
    Score: 0.183
  4. Predicting mortality within 1 year of ART initiation in children and adolescents living with HIV in sub-Saharan Africa: a retrospective observational cohort study. Lancet Glob Health. 2024 06; 12(6):e929-e937.
    View in: PubMed
    Score: 0.164
  5. HIV-associated pediatric tuberculosis: prevention, diagnosis and treatment. Curr Opin HIV AIDS. 2018 11; 13(6):501-506.
    View in: PubMed
    Score: 0.111
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.